These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 18986018

  • 1. [Evaluation of in vitro antibacterial activity of fosmidomycin and its derivatives].
    Shtannikov AV, Sergeeva EE, Biketov SF, Ostrovskiĭ DN.
    Antibiot Khimioter; 2007; 52(7-8):3-9. PubMed ID: 18986018
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of fosmidomycin analogs as inhibitors of the Synechocystis sp. PCC6803 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
    Woo YH, Fernandes RP, Proteau PJ.
    Bioorg Med Chem; 2006 Apr 01; 14(7):2375-85. PubMed ID: 16310360
    [Abstract] [Full Text] [Related]

  • 4. 1-Deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) from Mycobacterium tuberculosis: towards understanding mycobacterial resistance to fosmidomycin.
    Dhiman RK, Schaeffer ML, Bailey AM, Testa CA, Scherman H, Crick DC.
    J Bacteriol; 2005 Dec 01; 187(24):8395-402. PubMed ID: 16321944
    [Abstract] [Full Text] [Related]

  • 5. A fragment-based approach to understanding inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
    Mercklé L, de Andrés-Gómez A, Dick B, Cox RJ, Godfrey CR.
    Chembiochem; 2005 Oct 01; 6(10):1866-74. PubMed ID: 16116659
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Growth medium-dependent antimicrobial activity of early stage MEP pathway inhibitors.
    Sanders S, Bartee D, Harrison MJ, Phillips PD, Koppisch AT, Freel Meyers CL.
    PLoS One; 2018 Oct 01; 13(5):e0197638. PubMed ID: 29771999
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Crystal structure of 1-deoxy-d-xylulose 5-phosphate reductoisomerase from the hyperthermophile Thermotoga maritima for insights into the coordination of conformational changes and an inhibitor binding.
    Takenoya M, Ohtaki A, Noguchi K, Endo K, Sasaki Y, Ohsawa K, Yajima S, Yohda M.
    J Struct Biol; 2010 Jun 01; 170(3):532-9. PubMed ID: 20353826
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Novel deoxyxylulosephosphate-reductoisomerase inhibitors: fosmidomycin derivatives with spacious acyl residues.
    Ortmann R, Wiesner J, Silber K, Klebe G, Jomaa H, Schlitzer M.
    Arch Pharm (Weinheim); 2007 Sep 01; 340(9):483-90. PubMed ID: 17806130
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling.
    Zhang B, Watts KM, Hodge D, Kemp LM, Hunstad DA, Hicks LM, Odom AR.
    Biochemistry; 2011 May 03; 50(17):3570-7. PubMed ID: 21438569
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Isoprenoid biosynthesis via the methylerythritol phosphate pathway: structural variations around phosphonate anchor and spacer of fosmidomycin, a potent inhibitor of deoxyxylulose phosphate reductoisomerase.
    Zinglé C, Kuntz L, Tritsch D, Grosdemange-Billiard C, Rohmer M.
    J Org Chem; 2010 May 21; 75(10):3203-7. PubMed ID: 20429517
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.